)
Overview
<ul>
<li>Canada biopharma firm’s fiscal yr net loss widens to $7.2 mln</li>
<li>Operating expenses for fiscal yr rose to $7.9 mln</li>
</ul>
Outlook
<ul>
<li>Edesa aims to secure non-dilutive funding and collaborative arrangements</li>
</ul>
Result Drivers
<ul>
<li>VITILIGO PROGRAM EXPENSES - Increased R&amp;D expenses due to manufacturing activities for Phase 2 study of EB06 for vitiligo</li>
<li>R&amp;D EXPENSES - Research and development expenses increased by $0.8 million to $3.7 million</li>
</ul>
Key Details
Metric Beat/Mis Actual Consensu
s s
Estimate
<h3>FY EPS -$1.27</h3>
FY Net -$7.20
Income mln
<h3>FY $7.90</h3>
Operatin mln
g
Expenses
Analyst Coverage
<ul>
<li>The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 2 “strong buy” or “buy”, no “hold” and no “sell” or “strong sell”</li>
<li>The average consensus recommendation for the biotechnology &amp; medical research peer group is “buy”</li>
<li>Wall Street’s median 12-month price target for Edesa Biotech Inc is $9.00, about 408.5% above its December 11 closing price of $1.77</li>
</ul>
Press Release: For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

EDSA

Edesa Biotech reported a fiscal year net loss of $7.2 million, with operating expenses rising to $7.9 million. Increased R&D expenses were driven by manufacturing activities for a Phase 2 study of EB06 for vitiligo. Analysts rate the stock as a "buy," with a median 12-month price target of $9.00, significantly above its current price of $1.77.

Skin drug developer Edesa Biotech's FY net loss widens to $7.2 mln